Identification

Name
Meloxicam
Accession Number
DB00814  (APRD00529)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis, primary dysmenorrhea, fever; and as an analgesic, especially where there is an inflammatory component. It is closely related to piroxicam. In Europe it is marketed under the brand names Movalis, Melox, and Recoxa. In North America it is generally marketed under the brand name Mobic. In Latin America, the drug is marketed as Tenaron. [Wikipedia]

Structure
Thumb
Synonyms
  • Méloxicam
  • Meloxicam
  • Meloxicamum
  • UNII-vg2qf83cgl
External IDs
N-1539 / N1539 / UH-AC 62XX / UH-AC-62 XX / UH-AC62
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act MeloxicamTablet7.5 mgOralTeva2004-08-12Not applicableCanada
Act MeloxicamTablet15 mgOralTeva2004-08-12Not applicableCanada
Auro-meloxicamTablet15 mgOralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-meloxicamTablet7.5 mgOralAuro Pharma Inc2012-10-19Not applicableCanada
Ava-meloxicamTablet7.5 mgOralAvanstra Inc2011-11-082014-08-21Canada
Ava-meloxicamTablet15.0 mgOralAvanstra Inc2011-08-112014-08-21Canada
Dom-meloxicamTablet15 mgOralDominion Pharmacal2004-02-06Not applicableCanada
Dom-meloxicamTablet7.5 mgOralDominion Pharmacal2004-02-06Not applicableCanada
MeloxicamTablet7.5 mgOralSanis Health Inc2010-07-26Not applicableCanada
MeloxicamTablet15 mgOralPro Doc Limitee2009-06-10Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-meloxicamTablet7.5 mgOralApotex Corporation2004-02-13Not applicableCanada
Apo-meloxicamTablet15 mgOralApotex Corporation2004-02-13Not applicableCanada
Comfort Pac with MeloxicamKitPd Rx Pharmaceuticals, Inc.2010-06-30Not applicableUs
Comfort Pac with MeloxicamKitPd Rx Pharmaceuticals, Inc.2013-07-09Not applicableUs
MeloxicamTablet7.5 mg/1OralExelan Pharmaceuticals, Inc.2015-04-14Not applicableUs
MeloxicamTablet15 mg/1OralAv Pak2012-10-09Not applicableUs
MeloxicamTablet15 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2006-07-19Not applicableUs
MeloxicamTablet7.5 mg/1OralContract Pharmacy Services Pa2006-07-19Not applicableUs
MeloxicamTablet7.5 mg/1OralA S Medication Solutions2007-03-072017-06-20Us
MeloxicamTablet7.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-07-20Not applicableUs
International/Other Brands
Achefree (Achefree) / Acticam (Acromax Dominicana) / Aflamid (Anchor) / Afloxx (Lusa) / Aglan (Zentiva) / Ainecox (Cheminter) / Aldoron (Ivax) / Alentum (Lafrancol) / Algiflex (Biogen) / Aliviodol (Centrum) / Anaxicam (Caferma) / Anposel (Medipharm) / Antrend (Labormed) / Aponip (Pharmatec) / Areloger (Gerard) / Aremil (Magma) / Armex (Qintar Pharma) / Arrox (Xepa-Soul Pattinson) / Arsitec (Arsmedendi) / Artex (Pharmedic) / Arthrobic (Mekophar) / Arthrox (Pharmanel) / Articam (Standpharm) / Artipro (Helix) / Artriclox (Garmisch) / Artrifilm (G&R) / Artriflam (Sherfarma) / Artrilom (Pro.Med.CS) / Artrilox (Combiphar) / Artrox (PharmaBrand) / Aspicam (Biofarm) / Atiflam (Doctor Andreu) / Atrozan (Pharmstandard) / Auroxicam (Aurora) / Axius (Hersil) / Mobic
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Trepoxicam-7.5Meloxicam + HistidineKitPhysician Therapeutics Llc2011-01-312016-10-13Us
Categories
UNII
VG2QF83CGL
CAS number
71125-38-7
Weight
Average: 351.401
Monoisotopic: 351.034747299
Chemical Formula
C14H13N3O4S2
InChI Key
ZRVUJXDFFKFLMG-UHFFFAOYSA-N
InChI
InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)
IUPAC Name
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1λ⁶,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O

Pharmacology

Indication

For symptomatic treatment of arthritis and osteoarthritis.

Structured Indications
Pharmacodynamics

Meloxicam is an nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Prostaglandins are substances that contribute to inflammation of joints. Meloxicam inhibits prostaglandin synthetase (cylooxygenase 1 and 2) and leads to a decrease of the synthesis of prostaglandins, therefore, inflammation is reduced.

Mechanism of action

Anti-inflammatory effects of meloxicam are believed to be due to inhibition of prostaglandin synthetase (cylooxygenase), leading to the inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis may be associated with the analgesic and antipyretic effects of meloxicam.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Absolute bioavailability = 89%

Volume of distribution
  • 10 L
Protein binding

99.4% bound, primarily to albumin

Metabolism

Meloxicam is almost completely metabolized into inactive metabolites by the cytochrome P450 (CYP450) isozymes. CYP2C9 is primarily responsible for metabolism of meloxicam while CYP3A4 plays a minor role. An intermediate metabolite, 5'-hydroxymethyl meloxicam, is further metabolized to 5'-carboxy meloxicam, the major metabolite. Peroxidase activity is thought to produce the two other inactive metabolites of meloxicam.

Route of elimination

Meloxicam is almost completely metabolized to four pharmacologically inactive metabolites. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively.

Half life

15-20 hours

Clearance
  • 8.8 mL/min [Healthy Male Adults (Fed) oral 7.5 mg tablets]
  • 9.9 mL/min [Eldery Male (Fed) oral 15 mg capsules]
  • 5.1 mL/min [Eldery Female (Fed) oral 15 mg capsules]
  • 19 mL/min [Renal Failure (Fasted) oral 15 mg capsules]
  • 11 mL/min [Hepatic Insufficiency (Fasted) oral 15 mg capsules]
Toxicity

LD50, Acute: 84 mg/kg (Rat); Oral 470 mg/kg (Mouse); Oral 320 mg/kg (Rabbit)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Meloxicam Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Meloxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Meloxicam is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Meloxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabMeloxicam may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Meloxicam can be increased when it is combined with Abiraterone.Approved
AcebutololMeloxicam may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Acemetacin.Approved
AcenocoumarolMeloxicam may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinMeloxicam may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Meloxicam.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.Approved
AliskirenMeloxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Alminoprofen.Experimental
AlprenololMeloxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Meloxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Amcinonide.Approved
AmikacinMeloxicam may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMeloxicam may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Meloxicam can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Meloxicam.Approved, Investigational
AmrubicinMeloxicam may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMeloxicam may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Meloxicam is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Meloxicam is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Anisodamine.Investigational
annamycinMeloxicam may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Antipyrine.Approved
Antithrombin III humanMeloxicam may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMeloxicam may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Meloxicam is combined with Apocynin.Investigational
ApramycinMeloxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Meloxicam is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Meloxicam can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinMeloxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinMeloxicam may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMeloxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMeloxicam may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Atamestane.Investigational
AtazanavirThe metabolism of Meloxicam can be decreased when combined with Atazanavir.Approved, Investigational
AtenololMeloxicam may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Meloxicam can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meloxicam.Approved
BalsalazideMeloxicam may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminMeloxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMeloxicam may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMeloxicam may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Meloxicam.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meloxicam.Approved
BenorilateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Meloxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololMeloxicam may decrease the antihypertensive activities of Betaxolol.Approved
BevantololMeloxicam may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meloxicam.Approved, Investigational
BisoprololMeloxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMeloxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Meloxicam can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololMeloxicam may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Meloxicam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Meloxicam can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Meloxicam.Approved
BucillamineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bucillamine.Investigational
BucindololMeloxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bufexamac.Experimental
BufuralolMeloxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bumadizone.Experimental
BumetanideMeloxicam may decrease the diuretic activities of Bumetanide.Approved
BupranololMeloxicam may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Meloxicam.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Meloxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Meloxicam.Experimental
CapecitabineThe metabolism of Meloxicam can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Meloxicam.Approved
CarbamazepineThe metabolism of Meloxicam can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Meloxicam is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meloxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMeloxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMeloxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Meloxicam can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMeloxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Meloxicam can be increased when it is combined with Ceritinib.Approved
CertoparinMeloxicam may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meloxicam.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meloxicam.Approved
CholecalciferolThe metabolism of Meloxicam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meloxicam.Approved
CinoxacinMeloxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidMeloxicam may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Meloxicam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Meloxicam can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Meloxicam.Vet Approved
CloranololMeloxicam may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Meloxicam can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Meloxicam can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Meloxicam can be increased when it is combined with Conivaptan.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Meloxicam can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Meloxicam can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Meloxicam is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Meloxicam.Experimental
CyclosporineMeloxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Meloxicam is combined with D-Limonene.Investigational
Dabigatran etexilateMeloxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib.Approved
DalteparinMeloxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMeloxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanMeloxicam may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Meloxicam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Meloxicam can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinMeloxicam may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Meloxicam can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Meloxicam is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Meloxicam.Experimental
DelavirdineThe metabolism of Meloxicam can be decreased when combined with Delavirdine.Approved
DesirudinMeloxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meloxicam.Approved, Investigational
DextranMeloxicam may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Meloxicam may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Meloxicam may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Meloxicam may increase the anticoagulant activities of Dextran 75.Approved
DibekacinMeloxicam may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Meloxicam.Approved, Vet Approved
DicoumarolMeloxicam may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Meloxicam is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Meloxicam.Approved
DihydroergotamineThe metabolism of Meloxicam can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinMeloxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Meloxicam can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Meloxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meloxicam.Approved
DosulepinThe metabolism of Meloxicam can be decreased when combined with Dosulepin.Approved
DoxorubicinMeloxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Meloxicam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Meloxicam can be decreased when combined with Dronedarone.Approved
DrospirenoneMeloxicam may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Meloxicam is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Meloxicam is combined with E-6201.Investigational
Edetic AcidMeloxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMeloxicam may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Meloxicam can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Meloxicam.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Meloxicam.Approved
EnoxacinMeloxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinMeloxicam may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Meloxicam.Experimental
EnzalutamideThe serum concentration of Meloxicam can be decreased when it is combined with Enzalutamide.Approved
EpanololMeloxicam may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Meloxicam is combined with Epirizole.Approved
EpirubicinMeloxicam may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMeloxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meloxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meloxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Meloxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Equilin.Approved
ErythromycinThe metabolism of Meloxicam can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololMeloxicam may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Estrone sulfate.Approved
Etacrynic acidMeloxicam may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Meloxicam.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ethenzamide.Experimental
Ethyl biscoumacetateMeloxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Meloxicam.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Meloxicam can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Meloxicam is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Meloxicam is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Felbinac.Experimental
FelodipineThe metabolism of Meloxicam can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meloxicam.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Meloxicam.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Feprazone.Experimental
Ferulic acidMeloxicam may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Meloxicam.Approved, Investigational
FleroxacinMeloxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Meloxicam.Approved, Withdrawn
FloxuridineThe metabolism of Meloxicam can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Meloxicam is combined with fluasterone.Investigational
FluconazoleThe metabolism of Meloxicam can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fludrocortisone.Approved
FluindioneMeloxicam may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMeloxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Meloxicam can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Meloxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meloxicam.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Meloxicam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Meloxicam can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Meloxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxMeloxicam may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMeloxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Meloxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Meloxicam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Meloxicam can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Meloxicam.Approved
FosphenytoinThe metabolism of Meloxicam can be increased when combined with Fosphenytoin.Approved
FramycetinMeloxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMeloxicam may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Meloxicam can be increased when it is combined with Fusidic Acid.Approved
GabexateMeloxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMeloxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMeloxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Meloxicam.Approved, Withdrawn
GemfibrozilThe metabolism of Meloxicam can be decreased when combined with Gemfibrozil.Approved
GemifloxacinMeloxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMeloxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMeloxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMeloxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Meloxicam may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinMeloxicam may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Meloxicam is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Meloxicam is combined with HE3286.Investigational
HeparinMeloxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Higenamine.Investigational
HydralazineMeloxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meloxicam.Approved, Investigational
Hygromycin BMeloxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Meloxicam is combined with Icatibant.Approved
IdarubicinMeloxicam may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Meloxicam can be increased when it is combined with Idelalisib.Approved
IdraparinuxMeloxicam may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meloxicam.Approved, Investigational
ImatinibThe metabolism of Meloxicam can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Meloxicam.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam.Approved
IndenololMeloxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Meloxicam can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Indoprofen.Withdrawn
INNO-206Meloxicam may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Meloxicam can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Meloxicam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinMeloxicam may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Meloxicam can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Meloxicam is combined with Istaroxime.Investigational
ItraconazoleThe serum concentration of Meloxicam can be decreased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Meloxicam can be increased when it is combined with Ivacaftor.Approved
KanamycinMeloxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Meloxicam can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Meloxicam.Approved
LabetalolMeloxicam may decrease the antihypertensive activities of Labetalol.Approved
LandiololMeloxicam may decrease the antihypertensive activities of Landiolol.Investigational
LapatinibThe metabolism of Meloxicam can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Meloxicam.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Meloxicam.Approved, Investigational
LeflunomideThe metabolism of Meloxicam can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinMeloxicam may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMeloxicam may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololMeloxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMeloxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Meloxicam.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Meloxicam.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Meloxicam.Approved
LobeglitazoneThe metabolism of Meloxicam can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lonazolac.Experimental
LopinavirThe metabolism of Meloxicam can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Meloxicam can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Loteprednol.Approved
LovastatinThe metabolism of Meloxicam can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meloxicam.Approved, Investigational
LuliconazoleThe serum concentration of Meloxicam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Meloxicam can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Meloxicam is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Meloxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Meloxicam can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meloxicam.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Meloxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meloxicam.Approved
MelagatranMeloxicam may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Melengestrol.Vet Approved
MepindololMeloxicam may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineMeloxicam may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Meloxicam is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Meloxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMeloxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam.Approved
MetoprololMeloxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMeloxicam may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinMeloxicam may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Meloxicam can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Meloxicam can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Meloxicam.Approved
MitotaneThe serum concentration of Meloxicam can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Meloxicam.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Meloxicam.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meloxicam.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Meloxicam.Approved
NadololMeloxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMeloxicam may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMeloxicam may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Meloxicam.Approved
Nalidixic AcidMeloxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Meloxicam.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Meloxicam is combined with NCX 1022.Investigational
NeamineMeloxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololMeloxicam may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Meloxicam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Meloxicam can be decreased when combined with Nelfinavir.Approved
NemonoxacinMeloxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMeloxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Meloxicam.Approved
NetilmicinMeloxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Meloxicam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Meloxicam can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Meloxicam can be decreased when combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Meloxicam can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nitroaspirin.Investigational
NorfloxacinMeloxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
OlaparibThe metabolism of Meloxicam can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meloxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meloxicam.Approved
OlsalazineMeloxicam may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Meloxicam.Investigational
OmeprazoleThe metabolism of Meloxicam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Meloxicam can be increased when it is combined with Osimertinib.Approved
OtamixabanMeloxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxaprozin.Approved
Oxolinic acidMeloxicam may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololMeloxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxyphenbutazone.Approved, Withdrawn
PalbociclibThe serum concentration of Meloxicam can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Meloxicam is combined with Parecoxib.Approved
ParomomycinMeloxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Parthenolide.Investigational
PazufloxacinMeloxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMeloxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMeloxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateMeloxicam may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Meloxicam can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateMeloxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Meloxicam.Approved
PhenindioneMeloxicam may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Meloxicam can be increased when combined with Phenobarbital.Approved
PhenprocoumonMeloxicam may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meloxicam.Approved, Vet Approved
PhenytoinThe metabolism of Meloxicam can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meloxicam.Approved, Investigational
PindololMeloxicam may decrease the antihypertensive activities of Pindolol.Approved
PioglitazoneThe metabolism of Meloxicam can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidMeloxicam may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinMeloxicam may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMeloxicam may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pirfenidone.Approved, Investigational
Piromidic acidMeloxicam may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pirprofen.Experimental
Platelet Activating FactorMeloxicam may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinMeloxicam may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinMeloxicam may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Meloxicam.Approved
PosaconazoleThe metabolism of Meloxicam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololMeloxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Meloxicam.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Meloxicam can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Meloxicam can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Propacetamol.Approved, Investigational
PropranololMeloxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Meloxicam.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Meloxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Meloxicam.Vet Approved
Protein CMeloxicam may increase the anticoagulant activities of Protein C.Approved
Protein S humanMeloxicam may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMeloxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMeloxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Meloxicam is combined with PTC299.Investigational
PuromycinMeloxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Meloxicam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Meloxicam.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meloxicam.Approved
QuinineThe metabolism of Meloxicam can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Meloxicam can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Meloxicam.Approved
RanolazineThe metabolism of Meloxicam can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meloxicam.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinMeloxicam may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinMeloxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Meloxicam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Meloxicam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Meloxicam can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Risedronate.Approved, Investigational
RivaroxabanMeloxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Meloxicam.Investigational, Withdrawn
RosiglitazoneThe metabolism of Meloxicam can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinMeloxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinMeloxicam may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinMeloxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Meloxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meloxicam.Experimental
SaquinavirThe metabolism of Meloxicam can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Meloxicam.Investigational
SecobarbitalThe metabolism of Meloxicam can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Meloxicam is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Meloxicam is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Meloxicam is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Meloxicam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Meloxicam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Meloxicam can be increased when it is combined with Simeprevir.Approved
SisomicinMeloxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinMeloxicam may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Meloxicam.Approved
SorafenibThe metabolism of Meloxicam can be decreased when combined with Sorafenib.Approved, Investigational
SotalolMeloxicam may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMeloxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMeloxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinMeloxicam may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Meloxicam.Approved
SpironolactoneMeloxicam may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Meloxicam is combined with SRT501.Investigational
St. John's WortThe serum concentration of Meloxicam can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Meloxicam can be increased when it is combined with Stiripentol.Approved
StreptomycinMeloxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMeloxicam may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Meloxicam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Meloxicam can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meloxicam.Approved
SulfisoxazoleThe metabolism of Meloxicam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Meloxicam.Approved
SulodexideMeloxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Meloxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Suxibuzone.Experimental
TacrolimusMeloxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Meloxicam.Approved
TalinololMeloxicam may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Meloxicam.Approved
TamoxifenThe metabolism of Meloxicam can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Meloxicam.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Meloxicam is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Meloxicam can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Meloxicam can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meloxicam.Approved, Investigational
TemafloxacinMeloxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Meloxicam.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meloxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tepoxalin.Vet Approved
TeriflunomideThe metabolism of Meloxicam can be decreased when combined with Teriflunomide.Approved
TertatololMeloxicam may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Meloxicam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Meloxicam can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololMeloxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tixocortol.Approved
TobramycinMeloxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Meloxicam can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Meloxicam can be decreased when combined with Tolbutamide.Approved
TolevamerThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tolevamer.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meloxicam.Approved
TopiroxostatThe metabolism of Meloxicam can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideMeloxicam may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Meloxicam.Approved
TranilastThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meloxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meloxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Meloxicam is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMeloxicam may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
TrimethoprimThe metabolism of Meloxicam can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Meloxicam is combined with Triptolide.Investigational
TrovafloxacinMeloxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinMeloxicam may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Meloxicam.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Meloxicam.Investigational, Withdrawn
Valproic AcidThe metabolism of Meloxicam can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinMeloxicam may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Meloxicam can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Meloxicam.Approved
VenlafaxineThe metabolism of Meloxicam can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Meloxicam can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Meloxicam can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinMeloxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMeloxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Meloxicam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Meloxicam.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Meloxicam can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Meloxicam.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinMeloxicam may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinMeloxicam may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Laura Coppi, "Crystalline forms of meloxicam and processes for their preparation and interconversion." U.S. Patent US20030109701, issued June 12, 2003.

US20030109701
General References
Not Available
External Links
Human Metabolome Database
HMDB14952
KEGG Drug
D00969
KEGG Compound
C08169
PubChem Compound
54677470
PubChem Substance
46506624
ChemSpider
10442740
BindingDB
50056998
ChEBI
6741
ChEMBL
CHEMBL599
Therapeutic Targets Database
DAP000971
PharmGKB
PA450353
HET
MXM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Meloxicam
ATC Codes
M01AC56 — Meloxicam, combinationsM01AC06 — Meloxicam
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
PDB Entries
4m11 / 4o1z
FDA label
Download (45.4 KB)
MSDS
Download (35.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingNot AvailableSystemic Lupus Erythematosus (SLE)1
1CompletedNot AvailableHealthy Volunteers4
1CompletedTreatmentHealthy Volunteers8
2CompletedNot AvailableRheumatoid Arthritis1
2CompletedTreatmentDental Pain1
2CompletedTreatmentDysmenorrhea1
2CompletedTreatmentHysterectomy1
2CompletedTreatmentPain1
2CompletedTreatmentPharyngitis1
2CompletedTreatmentPost-Operative Pain1
2RecruitingTreatmentAnkylosing Spondylitis (AS)1
2RecruitingTreatmentHematopoietic Stem Cells / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusPreventionRupture; Graafian Follicle1
2WithdrawnTreatmentOsteoarthritis (OA)1
2, 3RecruitingTreatmentDysmenorrhea1
3CompletedNot AvailableRheumatoid Arthritis1
3CompletedTreatmentAnkylosing Spondylitis (AS)1
3CompletedTreatmentArthritis, Juvenile Rheumatoid2
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentLumbar Sciatic Pain1
3CompletedTreatmentOsteoarthritis (OA)2
3CompletedTreatmentPost-Operative Pain3
3CompletedTreatmentProstatic Neoplasms1
3CompletedTreatmentRheumatoid Arthritis1
3Not Yet RecruitingTreatmentOsteoarthritis (OA)1
3RecruitingTreatmentPostoperative pain1
3TerminatedTreatmentSurgery, Laparoscopic1
4CompletedPreventionOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedTreatmentBiliary Atresia, Kasai Portoenterostomy Status1
4CompletedTreatmentOsteoarthritis (OA)3
4CompletedTreatmentPharyngitis1
Not AvailableCompletedNot AvailableKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedNot AvailableRheumatoid Arthritis4
Not AvailableCompletedTreatmentInflammatory Reaction2
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableEnrolling by InvitationNot AvailableArthritis / Gout Acute / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1

Pharmacoeconomics

Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis totowa llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Beijing double crane pharmaceutical co ltd
  • Beijing yabao biopharmaceutical co ltd
  • Breckenridge pharmaceutical inc
  • Caraco pharmaceutical laboratories ltd
  • Carlsbad technology inc
  • Corepharma llc
  • Dr reddys laboratories inc
  • Genpharm inc
  • Glenmark generics ltd
  • Lupin pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Strides arcolab ltd
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Unichem laboratories ltd
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
TabletOral15.0 mg
Kit
SuspensionOral7.5 mg/5mL
Tablet7.5 mg/1
TabletOral15 mg/1
TabletOral7.5 mg/1
TabletOral15 mg
TabletOral7.5 mg
Kit
CapsuleOral10 mg/1
CapsuleOral5 mg/1
Prices
Unit descriptionCostUnit
Meloxicam 7.5 mg/5ml Suspension 100ml Bottle86.99USD bottle
Meloxicam bp powder56.61USD g
Mobic 15 mg tablet7.37USD tablet
Meloxicam 15 mg tablet4.94USD tablet
Mobic 7.5 mg tablet4.74USD tablet
Meloxicam 7.5 mg tablet3.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6184220Yes1999-09-252019-09-25Us
US9649318No2015-03-312035-03-31Us
US9526734No2013-03-312033-03-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)254 dec °CPhysProp
water solubility7.15 mg/LNot Available
logP3.43AVDEEF,A (1997)
Caco2 permeability-4.71ADME Research, USCD
pKa4.08MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.154 mg/mLALOGPS
logP2.28ALOGPS
logP1.6ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.47ChemAxon
pKa (Strongest Basic)0.47ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity88.62 m3·mol-1ChemAxon
Polarizability34.25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.9811
Caco-2 permeable+0.8484
P-glycoprotein substrateSubstrate0.5181
P-glycoprotein inhibitor INon-inhibitor0.7516
P-glycoprotein inhibitor IINon-inhibitor0.7491
Renal organic cation transporterNon-inhibitor0.9275
CYP450 2C9 substrateSubstrate0.5637
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.6649
CYP450 1A2 substrateNon-inhibitor0.9271
CYP450 2C9 inhibitorInhibitor0.5511
CYP450 2D6 inhibitorNon-inhibitor0.9322
CYP450 2C19 inhibitorNon-inhibitor0.8948
CYP450 3A4 inhibitorNon-inhibitor0.8191
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7316
Ames testNon AMES toxic0.8576
CarcinogenicityNon-carcinogens0.7052
BiodegradationNot ready biodegradable0.9312
Rat acute toxicity3.4619 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9579
hERG inhibition (predictor II)Non-inhibitor0.7999
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0009000000-d860614369de32fc5b55
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kf-0901000000-0d362af6b48e1604f3c0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-f79d2bd45c77067c33bf
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-385da9c2b565923f3591
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-24d8592c133da8552647
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uxr-0905000000-155a653652a8dc132b5c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uxu-2905000000-a1d5ee29626527977b8e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014l-3900000000-835e2ce927e75b3bb1fb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014l-3910000000-cf38e48efa983293e01f

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Not Available
Direct Parent
Benzothiazines
Alternative Parents
Alpha amino acids and derivatives / N-arylamides / 2,5-disubstituted thiazoles / Organosulfonamides / Benzenoids / 1,2-thiazines / Vinylogous acids / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds
show 4 more
Substituents
Alpha-amino acid or derivatives / Benzothiazine / N-arylamide / 2,5-disubstituted 1,3-thiazole / Ortho-thiazine / Benzenoid / Organosulfonic acid amide / Azole / Heteroaromatic compound / Vinylogous acid
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, 1,3-thiazole, benzothiazine (CHEBI:6741)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Poulsen Nautrup B, Horstermann D: [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs]. Dtsch Tierarztl Wochenschr. 1999 Mar;106(3):94-100. [PubMed:10220944]
  2. Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G: Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther. 1999 May;65(5):533-44. [PubMed:10340919]
  3. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057]
  4. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80. [PubMed:10381787]
  5. Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension. 1999 Nov;34(5):1163-7. [PubMed:10567199]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057]
  2. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80. [PubMed:10381787]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13. [PubMed:9493314]
  2. Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8. [PubMed:10381752]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13. [PubMed:9493314]
  2. Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8. [PubMed:10381752]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name
PGD
Uniprot ID
P52209
Uniprot Name
6-phosphogluconate dehydrogenase, decarboxylating
Molecular Weight
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Uchida Y, Kamiie J, Ohtsuki S, Terasaki T: Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96. Epub 2007 Oct 16. [PubMed:17939016]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34